0001493152-24-003984.txt : 20240126 0001493152-24-003984.hdr.sgml : 20240126 20240126171512 ACCESSION NUMBER: 0001493152-24-003984 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240123 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240126 DATE AS OF CHANGE: 20240126 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Dare Bioscience, Inc. CENTRAL INDEX KEY: 0001401914 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 204139823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36395 FILM NUMBER: 24568916 BUSINESS ADDRESS: STREET 1: 3655 NOBEL DRIVE STREET 2: SUITE 260 CITY: SAN DIEGO STATE: CA ZIP: 92122 BUSINESS PHONE: 858-926-7655 MAIL ADDRESS: STREET 1: 3655 NOBEL DRIVE STREET 2: SUITE 260 CITY: SAN DIEGO STATE: CA ZIP: 92122 FORMER COMPANY: FORMER CONFORMED NAME: Cerulean Pharma Inc. DATE OF NAME CHANGE: 20090714 FORMER COMPANY: FORMER CONFORMED NAME: Tempo Pharmaceuticals Inc DATE OF NAME CHANGE: 20070604 8-K 1 form8-k.htm
false 0001401914 Dare Bioscience, Inc. 0001401914 2024-01-23 2024-01-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 23, 2024

 

DARÉ BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36395   20-4139823
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (I.R.S. Employer
Identification No.)

 

3655 Nobel Drive, Suite 260

San Diego, CA 92122

(Address of Principal Executive Offices and Zip Code)

 

Registrant’s telephone number, including area code: (858) 926-7655

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock   DARE   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Changes in Management

 

Retirement of Chief Financial Officer

 

On January 23, 2024, Lisa Walters-Hoffert informed Daré Bioscience, Inc. (“our,” “we”, “us,” “our,” or the “Company”) that she will retire from all positions with the Company, and her employment with the Company will end, effective January 26, 2024. To help ensure a smooth transition of her responsibilities while also reducing costs for the Company over the long term, Ms. Walters-Hoffert and the Company agreed that she will transition to a consulting role with the Company. Ms. Walters-Hoffert currently serves as our Chief Financial Officer, a position she has held since July 2017. She co-founded the Company in 2015, and she has been actively involved since its inception.

 

On January 26, 2024, we and Ms. Walters-Hoffert entered into a consulting agreement pursuant to which she will provide us consulting services for a nine-month period (the “Consulting Period”). During the Consulting Period, we will pay her $31,667 per month and will reimburse her the amount of her health insurance premiums. In addition, Ms. Walters-Hoffert will remain eligible for a performance-based bonus for fiscal year 2023, even though she will not be employed on the date of payment. Ms. Walters-Hoffert’s consulting agreement contains a customary release of claims in our favor.

 

Given the current needs of the Company, we do not currently intend to appoint a chief financial officer. As further discussed below, the functions performed by a chief financial officer will be performed for us by Sabrina Martucci Johnson and MarDee Haring-Layton.

 

Appointment of Chief Accounting Officer

 

As a result of Ms. Walters-Hoffert’s retirement, Ms. Johnson, our Chief Executive Officer and President, will serve as our principal financial officer, and Ms. Haring-Layton, our current Vice President, Accounting & Finance, was appointed as our Chief Accounting Officer and will serve as our principal accounting officer. Ms. Johnson has extensive experience as a finance executive, having previously served as Chief Financial Officer at WomanCare Global Trading, a specialty pharmaceutical company in female reproductive healthcare, and Cypress Bioscience, a publicly-traded pharmaceutical company.

 

Ms. Haring-Layton, age 48, joined us in January 2018 and has served as our Vice President of Accounting & Finance since October 2018. She is a seasoned finance and accounting executive with more than 20 years of experience in financial reporting and accounting operations and with broad experience across both public and private companies as well as having Big 4 public accounting experience. Prior to joining us in 2018, Ms. Haring-Layton served as Chief Financial Officer of e.Digital Corporation, a publicly traded IP licensing and development company from 2010 until 2017. Earlier in her career, she held corporate accounting positions at public companies and provided consulting services for several biotechnology companies. She began her career with Deloitte, LLP. Ms. Haring-Layton has a Bachelor of Science in Business Administration (Accounting) from San Diego State University.

 

Ms. Haring-Layton’s current annual base salary is $295,000, which is the same amount it was during 2023. She also participates in our change in control policy, the terms of which are described on page 27 of our proxy statement for our 2023 Annual Meeting of stockholders under “Executive Compensation—Employment Agreements and Termination of Employment & Change in Control Arrangements” filed with the U.S. Securities and Exchange Commission on April 27, 2023.

 

Ms. Haring-Layton does not have any family relationships with any of our other executive officers or directors, nor was there any arrangement or understanding between Ms. Haring-Layton and any other person pursuant to which she was appointed as our Chief Accounting Officer, nor has she been involved in any related person transactions with us that would require disclosure under Item 404(a) of Regulation S-K.

 

-2-

 

 

Resignation of Chief Commercial Officer

 

On January 24, 2024, John Fair, our Chief Commercial Officer, informed us that, in light of the full-scale commercial launch of XACIATOTM—bringing to fruition one of his primary responsibilities as Chief Commercial Officer—he will be resigning from all positions with us and his employment with us will end effective June 30, 2024. Pursuant to a transition agreement we entered into with Mr. Fair on January 26, 2024, Mr. Fair will transition from full-time to part-time status, effective April 1, 2024. As of April 1, 2024, Mr. Fair will no longer serve as an executive officer of the Company. From April 1, 2024 to June 30, 2024 (the “Transition Period”), Mr. Fair will serve as an employee of the Company to help ensure a smooth transition of his responsibilities to other Company employees. We do not currently intend to hire a new full-time employee to serve as our chief commercial officer or in a similar position, thereby reducing costs for the Company over the long term. During the Transition Period, Mr. Fair’s base salary, which is currently an annualized amount of $386,000, will be reduced by 25%. Following his termination of employment, we expect to enter into a consulting agreement with Mr. Fair pursuant to which he will provide consulting services to us from time to time and we will compensate him at an hourly rate to be agreed upon if and when we enter into such consulting agreement and without any commitment by either party as to how many hours of consulting services Mr. Fair will provide.

 

Rightsizing Board of Directors

 

Following a periodic assessment by our Board of Directors (“Board”) of its size and composition, our Board determined that a reduction in the number of our directors would help rightsize the Board to our current operations and further align the size of our Board with boards of companies of similar size. As a result of this determination, on January 26, 2024, each of Cheryl R. Blanchard, Ph.D. and Sophia Ononye-Onyia, Ph.D. informed our Board that they will voluntarily resign from our Board immediately prior to our 2024 annual meeting of stockholders. Dr. Blanchard and Dr. Ononye-Onyia will continue to serve on our Board until our 2024 annual meeting of stockholders, at which time we expect to enter into advisory agreements with each of them pursuant to which they will serve as advisors to our Board and management for no additional cash compensation. The size of our Board will be reduced from eight to six members effective as of our 2024 annual meeting of stockholders. In addition, in connection with the periodic assessment, although it will not be a material cost savings, our Board also determined to reduce the annual cash compensation payable to non-employee directors to the 25th percentile of our peer group of companies.

 

Item 7.01 Regulation FD Disclosure.

 

The Company issued the press release attached hereto as Exhibit 99.1 with respect to the matters set forth in Item 5.02 above. The information in Item 7.01 of this report and Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any filing made under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

99.1 Press release issued January 26, 2024
104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

 

-3-

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  DARÉ BIOSCIENCE, INC.
   
Dated: January 26, 2024 By: /s/ Sabrina Martucci Johnson             
  Name:  Sabrina Martucci Johnson
  Title: President and Chief Executive Officer

 

-4-

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

Daré Bioscience Announces Executive Team and Board of Directors Changes

 

SAN DIEGO, JAN. 26, 2024 — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced changes in company management which includes the retirement of Chief Financial Officer, Lisa Walters-Hoffert, and the resignation of Chief Commercial Officer, John Fair. Both Ms. Walters-Hoffert and Mr. Fair have entered into plans with the Company to help ensure a seamless transition. Daré also announced an adjustment to the size of its Board of Directors to better reflect the Company’s size following the voluntary resignations of Cheryl R. Blanchard, Ph.D. and Sophia Ononye-Onyia, Ph.D.

 

“On behalf of the Daré team, I am so grateful to Lisa and John for their invaluable contributions to the Company and women’s health as a whole, including Lisa’s pivotal role in our founding, and John’s expertise and guidance to help bring forward our first commercial product XACIATO™. We also appreciate Dr. Blanchard’s and Dr. Ononye-Onyia’s seasoned counsel and insights as Board members and their future support as advisors,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. “As we continue to execute on our mission, these changes further support our focus on advancing our late-stage product candidates, Ovaprene® and Sildenafil Cream, 3.6%, as well as maintaining a lean cost structure and creating long-term value for all Daré stakeholders.”

 

Retirement of Chief Financial Officer

 

On January 23, 2024, Co-founder and Chief Financial Officer Lisa Walters-Hoffert informed Daré that she will retire from all positions with the Company, effective January 26, 2024. To help ensure a smooth transition of her responsibilities, Ms. Walters-Hoffert and the Company agreed that she will transition to a nine-month consulting role with the Company following her retirement.

 

Given the financial knowledge and experience within the Daré team, the Company does not currently intend to appoint a chief financial officer, which further reduces costs for the Company over the long term as well. The functions performed by a chief financial officer will be performed by Ms. Johnson and MarDee Haring-Layton going forward.

 

Appointment of Chief Accounting Officer

 

As a result of Ms. Walters-Hoffert’s retirement, Ms. Johnson, our Chief Executive Officer and President, will serve as our principal financial officer, and MarDee Haring-Layton, our current Vice President, Accounting & Finance, will serve as our Chief Accounting Officer. Ms. Johnson has extensive experience as a finance executive, having previously served as Chief Financial Officer at WomanCare Global Trading, a specialty pharmaceutical company in female reproductive healthcare, and Cypress Bioscience, a publicly-traded pharmaceutical company.

 

Ms. Haring-Layton joined us in January 2018 and has served as our Vice President of Accounting & Finance since October 2018. She is a seasoned finance and accounting executive with more than 20 years of experience in financial reporting and accounting operations, with broad experience across both public and private companies as well as having Big 4 public accounting experience. Prior to joining Daré in 2018, Ms. Haring-Layton served as Chief Financial Officer of e.Digital Corporation, a publicly traded IP licensing and development company from 2010 until 2017. Earlier in her career, she held corporate accounting positions at public companies and provided consulting services for several biotechnology companies. She began her career with Deloitte, LLP. Ms. Haring-Layton has a Bachelor of Science in Business Administration (Accounting) from San Diego State University.

 

1

 

 

Resignation of Chief Commercial Officer

 

On January 24, 2024, Mr. Fair, our Chief Commercial Officer, informed us that, in light of the full-scale commercial launch of XACIATOTM—bringing to fruition one of his primary responsibilities as Chief Commercial Officer—he will be resigning from all positions with Daré and his employment will end June 30, 2024. We do not currently intend to hire a new full-time employee to serve as our chief commercial officer or in a similar position, thereby reducing costs for the Company over the long term.

 

Rightsizing Board of Directors

 

Following a periodic assessment by our Board of Directors of its size and composition, our Board determined that a reduction in the number of directors would help rightsize the Board to our current operations and further align the size of our Board with boards of companies of similar size. As a result of this determination, on January 26, 2024, each of Cheryl R. Blanchard, Ph.D. and Sophia Ononye-Onyia, Ph.D. informed our Board that they will voluntarily resign from our Board immediately prior to our 2024 annual meeting of stockholders.

 

Dr. Blanchard and Dr. Ononye-Onyia will continue to serve on our Board until our 2024 annual meeting of stockholders, at which time we expect to enter into advisory agreements with each of them pursuant to which they will serve as advisors to our Board and management for no additional cash compensation. The size of our Board will be reduced from eight to six members effective as of our 2024 annual meeting of stockholders. In addition, in connection with the periodic assessment, our Board also determined to reduce the annual cash compensation payable to non-employee directors to the 25th percentile of our peer group of companies.

 

About Daré Bioscience

 

Daré Bioscience is a biopharmaceutical company committed to advancing innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women’s health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, vaginal health, reproductive health, menopause, sexual health and fertility.

 

Daré’s first FDA-approved product, XACIATO™ (clindamycin phosphate) vaginal gel 2% is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Daré’s portfolio also includes potential first-in-category candidates in clinical development: Ovaprene®, a novel, hormone-free monthly intravaginal contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil, the active ingredient in Viagra®, to treat female sexual arousal disorder (FSAD); and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy. To learn more about XACIATO, Daré’s full portfolio of women’s health product candidates, and Daré’s mission to deliver differentiated therapies for women, please visit www.darebioscience.com.

 

2

 

 

Daré Bioscience leadership has been named on the Medicine Maker’s Power List and Endpoints News’ Women in Biopharma 2022. In 2023, Daré’s CEO was honored as one of Fierce Pharma’s Most Influential People in Biopharma for Daré’s contributions to innovation and advocacy in the women’s health space. Daré Bioscience placed #1 in the Small Company category of the San Diego Business Journal’s 2023 Best Places to Work Awards.

 

Daré may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company and may also use social media to communicate important information about the company, its finances, product and product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these X (formerly Twitter) accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Daré’s website.

 

Contacts:

 

Media and Investors on behalf of Daré Bioscience, Inc:

 

Camilla White / Simona Kormanikova

Dentons Global Advisors

DareBioscience@dentonsglobaladvisors.com / 1.212.466.6450

 

Source: Daré Bioscience, Inc.

 

3

 EX-101.SCH 3 dare-20240123.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 dare-20240123_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 dare-20240123_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Cover
Jan. 23, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 23, 2024
Entity File Number 001-36395
Entity Registrant Name Dare Bioscience, Inc.
Entity Central Index Key 0001401914
Entity Tax Identification Number 20-4139823
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 3655 Nobel Drive
Entity Address, Address Line Two Suite 260
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92122
City Area Code (858)
Local Phone Number 926-7655
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock
Trading Symbol DARE
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001401914 2024-01-23 2024-01-23 iso4217:USD shares iso4217:USD shares false 0001401914 Dare Bioscience, Inc. 8-K 2024-01-23 DE 001-36395 20-4139823 3655 Nobel Drive Suite 260 San Diego CA 92122 (858) 926-7655 false false false false Common stock DARE NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://darebioscience.com/role/Cover Cover Cover 1 false false All Reports Book All Reports dare-20240123.xsd dare-20240123_lab.xml dare-20240123_pre.xml form8-k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "DARE", "nsuri": "http://darebioscience.com/20240123", "dts": { "schema": { "local": [ "dare-20240123.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "dare-20240123_lab.xml" ] }, "presentationLink": { "local": [ "dare-20240123_pre.xml" ] }, "inline": { "local": [ "form8-k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://darebioscience.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-01-23", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-01-23", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://darebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001493152-24-003984-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-003984-xbrl.zip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